An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Public ClinicalTrials.gov record NCT07197866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Study identification
- NCT ID
- NCT07197866
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2025
- Primary completion
- May 2, 2029
- Completion
- May 16, 2029
- Last update posted
- Aug 30, 2026
2025 – 2029
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 15554 | La Jolla | California | 92037 | Recruiting |
| Teva Investigational Site 15544 | Boca Raton | Florida | 33486 | Recruiting |
| Teva Investigational Site 15555 | Tampa | Florida | 33613 | Recruiting |
| Teva Investigational Site 15546 | Kansas City | Kansas | 66160 | Recruiting |
| Teva Investigational Site 15549 | New York | New York | 10016 | Recruiting |
| Teva Investigational Site 15551 | New York | New York | 10032-3726 | Recruiting |
| Teva Investigational Site 15548 | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| Teva Investigational Site 15543 | Spokane | Washington | 99202 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07197866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07197866 live on ClinicalTrials.gov.